Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials-Reference-Cited by-同舟云学术

Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials

Published:2022-10-28 Issue: Volume: Page:
ISSN:1939-5116
Container-title:WIREs Nanomedicine and Nanobiotechnology
language:en
Short-container-title:WIREs Nanomed Nanobiotechnol

Author:

DuRoss Allison N.¹,Phan Jack²,Lazar Alexander J.³,Walker Joshua M.⁴,Guimaraes Alexander R.⁵,Baas Carole⁶,Krishnan Sunil⁷^ORCID,Thomas Charles R.⁴⁸,Sun Conroy¹⁴^ORCID,Bagley Alexander F.²⁴⁹^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences Oregon State University Portland Oregon USA

2. Department of Radiation Oncology, Division of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Department of Pathology and Department of Genomic Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA

4. Department of Radiation Medicine Oregon Health & Science University Portland Oregon USA

5. Department of Diagnostic Radiology Oregon Health & Science University Portland Oregon USA

6. National Cancer Institute Bethesda Maryland USA

7. Department of Radiation Oncology Mayo Clinic Florida Jacksonville Florida USA

8. Department of Radiation Oncology, Norris Cotton Cancer Center Dartmouth University Lebanon New Hampshire USA

9. Department of Radiation Oncology Samaritan Health Services Corvallis Oregon USA

Funder

American Society for Radiation Oncology

National Cancer Institute

National Institute of Dental and Craniofacial Research

National Institute of General Medical Sciences

Publisher

Wiley

Subject

Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/wnan.1867

Reference73 articles.

1. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

2. The Chameleon effect: Characterization challenges due to the variability of nanoparticles and their surfaces;Baer D. R.;Frontiers in Chemistry,2018

3. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience

4. First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas

5. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers;Frontiers in Oncology;2024-08-13

2. Targeting the organelle for radiosensitization in cancer radiotherapy;Asian Journal of Pharmaceutical Sciences;2024-04

3. The Impact of Nanomedicine on Soft Tissue Sarcoma Treated by Radiotherapy and/or Hyperthermia: A Review;Cancers;2024-01-17

4. Current research trends of nanomedicines;Acta Pharmaceutica Sinica B;2023-11

5. Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy;Strahlentherapie und Onkologie;2023-04-11